The effects of SERMs on the skeleton

Journal of Endocrinological Investigation

Volumn 22, Issue 8, 1999, Pages 604-608

  Tobias, J H ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bone mineral density; Bone turnover; Fracture risk; SERM

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BONE DENSITY; BONE MINERAL; BREAST; CLINICAL STUDY; CLINICAL TRIAL; FRACTURE; HUMAN; MOUSE; NONHUMAN; OSTEOPOROSIS; REVIEW; RISK FACTOR; SKELETON; UTERUS;

EID: 0032848212     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343617     Document Type: Review

References (28)

1. Kalu D.N. The ovariectomised rat model of postmenopausal bone loss. Bone Miner. 1991, 15: 175-192.
2. Ke H.Z., Simmons H.A., Pirie C.M., et al. Droloxifene, a newestrogen antagonist/agonist, prevents bone loss in ovariectomised rats. Endocrinology 1995, 136: 2435-2441.
3. Turner R.T., Wakeley G.K., Hannon K.S., et al. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. Bone Min. Res. 1987, 2: 449-456.
4. Evans G., Bryant H.U., Magee D., et al. The effects of raloxifene on tibia histomorphometry in ovariectomised rats. Endocrinology 1994, 134: 2283-2288.
5. Sato M., Zeng G.Q., Rowley E., et al. LY353381.HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34). Endocrinology 1998, 139: 4642-4651.
6. Jimenez M.A., Maghee D.E., Bryant H.U., et al. Clomiphene prevents cancellous bone loss from the tibia of ovariectomised rats. Endocrinology 1997, 138: 1794-1800.
7. Nuttall M.E., Bradbeer J.N., Stroup G.B., et al. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomised rats and decreases uterine weight in intact rats. Endocrinology 1998, 139: 5224-5234.
8. Sibonga J.D., Dobnig H., Harden R.M., et al. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 1998, 139: 3736-3742.
9. Tobias J.H., Compston J.E. Does estrogen stimulate osteoblast function in postmenopausal women? Bone 1999, 24: 121-124.
10. Samuels A., Perry M.J., Tobias J.H. High-dose estrogen induces medullary bone formation in female mice. Bone Min. Res. 1999, 14: 178-186.
11. Bain S.D., Bailey M.C., Celino D.L., et al. High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomised mouse. Bone Min. Res. 1993, 8: 435-442.
12. Hassager C., Colwell A., Assiri A.M.A., et al. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin. Endocrinol. 1992, 37: 45-50.
13. Christiansen C., Christiansen M.S., Larsen N.-E., et al. Pathophysiological mechanism of estrogen effect on bone metabolism: dose-response relationship in early postmenopausal women. Clin. Endocrinol. Metab. 1982, 55: 1124-1130.
14. Lufkin E.G., Whitaker M.D., Nickelsen T., et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomised trial. J. Bone Min. Res. 1998, 13: 1747-1754.
15. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641-1647.
16. Draper M.W., Flowers D.E., Huster W.J., et al. A controlled trial of raloxifene: impact on bone turnover and serum profile in healthy postmenopausal women. Bone Min. Res. 1996, 11: 835-842.
17. Heaney R.P., Draper M.W. Raloxifene and estrogen: comparative bone-remodeling kinetics. Clin. Endocrinol. Metab. 1997, 82: 3425-3429.
18. Marttunen M.B., Hietanen P., Tiitinen A., et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenausal breast cancer patients. Clin. Endocrinol. Metab. 1998, 83: 1158-1162.
19. Love R.R., Mazees R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 1992, 326: 852-856.
20. Meunier P.J., Vignot E., Garnero P., et al. Postmenopausal women with osteoporosis: effects of raloxifene on bone mineral density in the hip and lumbar spine. Bone 1998, 23: 5295.
21. Chesnut C., Weiss S., Mulder H., et al. Idoxifene increases bone mineral density in osteopenic postmenopausal women. Bone 1998, 23 (Suppl.): S389.
22. Christiansen C, Riis B.J. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. Clin. Endocrinool. Metab. 1990, 71: 836-841.
23. Lindsay R., Tohme J.F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynaecol. 1990, 76: 290-295.
24. Lufkin E.G., Wahner H.W., O'Fallon W.M., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992, 117: 1-9.
25. Fisher B., Costantino J.P., Wickerman D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Natl. Cancer Inst. 1998, 90: 1371-1388.
26. Delmas P.D., Ensrud K.E., Harris S., et al. Raloxifene therapy for three years reduces the risk of incident vertebral fractures in postmenopausal women. Calcif. Tissue Int. 1993, 64 (Suppl. 1): S43.
27. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 1998, 339: 292-299.
28. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent cyclical etidronate therapy in the prevention of corticosteroid-induced osteoporosis. N. Engl. J. Med. 1997, 337: 382-387.